8.82

1.15% 0.10

After Hours: 8.82

Grifols Sa Adr (GRFS)

Overview News Price History Option Chain Why GRFS Down? Discussions Forecast Stock Split Dividend History

Grifols Sa Adr stock is traded at $8.82, with a volume of 530.80K. It is up +1.15% in the last 24 hours and up +22.16% over the past month. Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.

Previous Close:

$8.72

Open:

$8.74

24h Volume:

530.80K

Relative Volume:

0.56

Market Cap:

$5.65B

Revenue:

$7.94B

Net Income/Loss:

$225.54M

P/E Ratio:

26.74

EPS:

0.3299

Net Cash Flow:

$709.16M

1W Performance:

+6.14%

1M Performance:

+22.16%

6M Performance:

+20.82%

1Y Performance:

+17.44%

1-Day Range:

$8.73

$8.92

1-Week Range:

$8.20

$8.92

52-Week Range:

$5.79

$9.96

Grifols Sa Adr Stock (GRFS) Company Profile

Name

Grifols Sa Adr

Sector

Healthcare (1170)

Industry

Drug Manufacturers - General (20)

Phone

Address

Employee

23,822

Twitter

Next Earnings Date

2024-11-07

Latest SEC Filings

GRFS's Discussions on Twitter

Compare GRFS with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
GRFS Grifols Sa Adr	8.82	5.65B	7.94B	225.54M	709.16M	0.3299
LLY Lilly Eli Co	769.88	662.23B	49.00B	11.11B	-1.27B	12.29
JNJ Johnson Johnson	155.03	373.45B	89.33B	21.81B	18.57B	8.99
ABBV Abbvie Inc	189.83	328.75B	57.37B	4.20B	15.39B	2.35
NVO Novo Nordisk Adr	74.63	317.70B	43.59B	15.04B	10.74B	3.3766
NVS Novartis Ag Adr	118.02	228.64B	53.22B	12.86B	14.85B	6.39

Grifols Sa Adr Stock (GRFS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-12-25	Resumed	Morgan Stanley	Overweight
Mar-12-24	Downgrade	Deutsche Bank	Hold → Sell
Apr-12-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Mar-03-23	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Feb-16-23	Upgrade	Barclays	Underweight → Equal Weight
Jan-18-23	Upgrade	Jefferies	Hold → Buy
Apr-08-22	Initiated	Morgan Stanley	Equal-Weight
Nov-05-21	Downgrade	Deutsche Bank	Buy → Hold
Oct-19-21	Downgrade	Barclays	Overweight → Underweight
Oct-06-21	Upgrade	Citigroup	Neutral → Buy
Jun-14-21	Upgrade	Deutsche Bank	Hold → Buy
Apr-20-21	Initiated	Deutsche Bank	Hold
Mar-23-21	Upgrade	Credit Suisse	Neutral → Outperform
Mar-11-21	Upgrade	HSBC Securities	Hold → Buy
Oct-01-20	Upgrade	Citigroup	Sell → Neutral
Jun-09-20	Downgrade	Citigroup	Neutral → Sell
Jun-09-20	Upgrade	HSBC Securities	Reduce → Hold
Mar-25-20	Downgrade	Citigroup	Buy → Neutral
Jun-27-19	Upgrade	JP Morgan	Neutral → Overweight
Feb-08-19	Downgrade	Berenberg	Buy → Hold
Oct-11-18	Upgrade	Berenberg	Hold → Buy
Jun-01-18	Initiated	Barclays	Overweight
Oct-31-17	Initiated	Citigroup	Buy
Jun-30-17	Downgrade	Goldman	Buy → Neutral
Apr-06-17	Initiated	BofA/Merrill	Buy
Jan-03-17	Upgrade	JP Morgan	Neutral → Overweight
Feb-09-16	Upgrade	Berenberg	Hold → Buy
Jan-04-16	Downgrade	Morgan Stanley	Equal-Weight → Underweight
Dec-02-15	Downgrade	HSBC Securities	Buy → Hold
Nov-20-15	Downgrade	Berenberg	Buy → Hold
Apr-28-15	Downgrade	Berenberg	Buy → Hold

View All

Grifols Sa Adr Stock (GRFS) Latest News

May 28, 2025

ADMA Biologics Vs. Grifols: Which Plasma Therapy Stock Is The Better Buy? - Barchart.com

May 28, 2025

May 22, 2025

Grifols: If This Works Out, It Has Massive Upside (NASDAQ:GRFS) - Seeking Alpha

May 22, 2025

May 02, 2025

Grifols S.A. Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm - ACCESS Newswire

May 02, 2025

Apr 28, 2025

SMRT’s latest rating updates from top analysts. - knoxdaily.com

Apr 28, 2025

Investing in Grifols SA ADR (GRFS): What You Must Know - knoxdaily.com

Apr 28, 2025

Investing in Apellis Pharmaceuticals Inc (APLS) Is Getting More Attractive - knoxdaily.com

Apr 28, 2025

A company insider recently sold 10,000 shares of News Corp [NWSA]. Should You also Consider to Sale? - knoxdaily.com

Apr 28, 2025

Raymond James Downgrades Truist Financial Corporation (TFC) to a Mkt perform from an Outperform - knoxdaily.com

Apr 28, 2025

AT&T, Inc (T) rating upgrades by Exane BNP Paribas - knoxdaily.com

Apr 28, 2025

Apr 25, 2025